{
    "2019-07-09": [
        [
            {
                "time": "2019-07-09",
                "original_text": "Bayer-J&J Announce Positive Xarelto Data in Children with VTE",
                "features": {
                    "keywords": [
                        "Bayer",
                        "J&J",
                        "Xarelto",
                        "Positive",
                        "Data",
                        "Children",
                        "VTE"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "Intra-Cellular Therapies' Candidate Fails in Phase III Study",
                "features": {
                    "keywords": [
                        "Intra-Cellular",
                        "Therapies",
                        "Candidate",
                        "Fails",
                        "Phase",
                        "III",
                        "Study"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "Long-Acting",
                        "HIV",
                        "Regimen",
                        "FDA",
                        "Priority",
                        "Status"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "Can Johnson & Johnson (JNJ) Keep the Earnings Surprise Streak Alive?",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "Earnings",
                        "Surprise",
                        "Streak"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "Earnings",
                        "Expected",
                        "Grow",
                        "Buy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "Judge rules against Trump on drug pricing disclosures",
                "features": {
                    "keywords": [
                        "Judge",
                        "rules",
                        "against",
                        "Trump",
                        "drug",
                        "pricing",
                        "disclosures"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "policy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "Top",
                        "Dividend",
                        "Stock",
                        "Buy"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "Health Care Sector Update for 07/09/2019: CHEK, ALT, IMMP, JNJ, PFE, ABT, MRK, AMGN",
                "features": {
                    "keywords": [
                        "Health",
                        "Care",
                        "Sector",
                        "Update",
                        "CHEK",
                        "ALT",
                        "IMMP",
                        "JNJ",
                        "PFE",
                        "ABT",
                        "MRK",
                        "AMGN"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "With new execs on board, Celsius signs Janssen deal",
                "features": {
                    "keywords": [
                        "new",
                        "execs",
                        "Celsius",
                        "Janssen",
                        "deal"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "partnerships"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "See what the IHS Markit Score report has to say about Johnson & Johnson.",
                "features": {
                    "keywords": [
                        "IHS",
                        "Markit",
                        "Score",
                        "report",
                        "Johnson",
                        "&",
                        "Johnson"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-09",
                "original_text": "J&J and Microsoft Among Defensive Stocks With Positive Earnings Outlooks",
                "features": {
                    "keywords": [
                        "J&J",
                        "Microsoft",
                        "Defensive",
                        "Stocks",
                        "Positive",
                        "Earnings",
                        "Outlooks"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}